metaEvidence - overview


			deaths (OS)	progression or deaths (PFS)	RFS/DFS
metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2)
mNSCLC - L2 - all population metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) mNSCLC - L2 - all population
mNSCLC - L2 - EGFR mutant metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) mNSCLC - L2 - EGFR mutant
versus osimertinib
	durvalumab plus osimertinib vs. osimertinib	1	1524 [-1402; 4449] /10000 4/14 vs. 2/15	190 [-3067; 3448] /10000 4/14 vs. 4/15	-
mNSCLC - L2 - PDL1 negative metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) mNSCLC - L2 - PDL1 negative
mNSCLC - L2 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) mNSCLC - L2 - PDL1 positive
versus Standard of Care (SoC)
	durvalumab alone vs. Standard of Care (SoC)	1	-852 [-2197; 493] /10000 48/62 vs. 55/64	292 [-648; 1233] /10000 58/62 vs. 58/64	-
non squamous - mNSCLC - L2 - all population metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) non squamous cell - mNSCLC - L2 non squamous - mNSCLC - L2 - all population
squamous - mNSCLC - L2 - all population metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) squamous cell - mNSCLC - L2 squamous - mNSCLC - L2 - all population